"At the end of the inspection, the facility received 9 observations, with no repeat observations and mostly procedural in nature," Natco Pharma said in a BSE filing.from Healthcare/Biotech-Industry-Economic Times http://bit.ly/31epWg0
via IFTTT
USFDA issues 9 observations to Natco Pharma's Kothur facility
"At the end of the inspection, the facility received 9 observations, with no repeat observations and mostly procedural in nature," Natco Pharma said in a BSE filing.from Healthcare/Biotech-Industry-Economic Times http://bit.ly/31epWg0
via IFTTT
0 comments:
Post a Comment